EU Regulating AI ‘Like A Microwave’ When Focus Should Be Its Ability To Cook

Concerns are mounting over how the EU’s AI Act will impact the medtech sector. Now, a computer science expert has argued that the proposed regulation is fundamentally flawed in its approach, because it puts the focus on the AI product instead of its output.

The European Commission’s proposal for a horizontal regulation that applies to all artificial intelligence (AI) products has been largely met with skepticism from stakeholders across the medtech industry. So far, much of this criticism has focused on the overlap between the AI Act and other regulations in the EU, such as the sector-specific Medical Device and In Vitro Diagnostic Regulations (MDR/IVDR).

A wider perspective on the AI Act and its “fundamental problem” was offered by a philosopher and computer ethics professor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

11 Jul 2025

• By Amanda Maxwell

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

10 Jul 2025

• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

10 Jul 2025

• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

09 Jul 2025

• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.